Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Aug 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 27 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
- 08 Aug 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.